Mark Massaro, an analyst from BTIG, reiterated the Buy rating on BillionToOne, Inc. Class A. The associated price target remains the same with $160.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mark Massaro has given his Buy rating due to a combination of factors that highlight BillionToOne, Inc.’s strong financial performance and growth potential. The company reported impressive revenue growth of 117% year-over-year and achieved its first quarter of positive net income, showcasing its financial strength as a newly public entity. Additionally, BillionToOne’s operating margin of 11.5% and positive GAAP EPS are notable achievements for an early-stage company, indicating robust operational efficiency.
Furthermore, the company’s guidance for Q4 2025 revenue exceeds expectations, demonstrating confidence in continued growth. BillionToOne is also making significant strides in the oncology market, with substantial increases in both prenatal and oncology test revenues. The upcoming implementation of Epic Aura and the anticipated launch of the minimal residual disease test further bolster the company’s growth prospects. These strategic initiatives, combined with a solid financial foundation, underpin Massaro’s Buy rating and the $160 price target.
Massaro covers the Healthcare sector, focusing on stocks such as Exact Sciences, Zoetis, and CareDx. According to TipRanks, Massaro has an average return of -2.3% and a 34.56% success rate on recommended stocks.
In another report released on December 1, Piper Sandler also initiated coverage with a Buy rating on the stock with a $150.00 price target.